Johnson & Johnson (JNJ) Interest Coverage Ratio (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Interest Coverage Ratio came in at 25.41 in Q2 2026, up 17.76% year-over-year from 21.58 in Q2 2025, and up 8.62% quarter-over-quarter from 23.39 in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Interest Coverage Ratio across 18 years of filings, most recently posting 25.41 for Q2 2026.
- In Q2 2026, Interest Coverage Ratio rose 17.76% year-over-year to 25.41; the TTM figure through Jun 2026 stood at 25.73 (up 0.95% YoY), while the FY2025 annual figure was 26.13, down 6.14% from the prior year.
- Interest Coverage Ratio came in at 25.41 for Q2 2026 at Johnson & Johnson, up from 23.39 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 435.2 in Q2 2022 to a low of 21.58 in Q2 2025.
- Average Interest Coverage Ratio over 5 years is 59.3, with a median of 27.56 recorded in 2023.
- Year-over-year, Interest Coverage Ratio surged 315.73% in 2022 and slumped 93.8% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 103.9 in 2022, then tumbled by 72.9% to 28.15 in 2023, then dropped by 6.69% to 26.27 in 2024, then fell by 2.04% to 25.73 in 2025, then retreated by 1.26% to 25.41 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 25.41 in Q2 2026, 23.39 in Q1 2026, and 25.73 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | - |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 10.28 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 3.65 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | -21.24 |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1,199.14 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 114.07 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 52.24 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 25.41 |
| Mar 29, 2026 | 23.39 |
| Dec 28, 2025 | 25.73 |
| Sep 28, 2025 | 28.71 |
| Jun 29, 2025 | 21.58 |
| Mar 30, 2025 | 30.30 |
| Dec 29, 2024 | 26.27 |
| Sep 29, 2024 | 26.10 |
| Jun 30, 2024 | 23.96 |
| Mar 31, 2024 | 38.12 |
| Dec 31, 2023 | 28.15 |
| Oct 1, 2023 | 29.90 |
| Jul 2, 2023 | 26.79 |
| Apr 2, 2023 | 26.96 |
| Jan 1, 2023 | 44.88 |
| Oct 2, 2022 | 103.90 |
| Jul 3, 2022 | 102.08 |
| Apr 3, 2022 | 435.20 |
| Oct 3, 2021 | 330.30 |
| Jul 4, 2021 | 155.05 |